Linda Marbán, Capricor CEO
Capricor hits primary endpoint in Duchenne extension study, readying its FDA pitch
It has been a very bumpy ride for Capricor Therapeutics over the past several years, including a halted J&J partnership and venture into penny …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
